Search the Newsreel

Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), focusing on its PE, PB, and fair value. It includes current stock performance metrics and links to further financial data and company overviews.

Enterprise value to revenue forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL

Immunocore Holdings PLC (IMCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immunocore Holdings PLC (IMCR), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, IMCR's price momentum score is 3.98, and the stock is trading between a resistance of …

LYEL|Lyell Immunopharma Inc|Price:13.000|Chg%:+0.040

TradingKey provides a comprehensive stock analysis for Lyell Immunopharma Inc (LYEL), highlighting its relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a late-stage clinical entity developing CAR T-cell therapies, has high institutional ownership and …

Immunic Inc (IMUX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Immunic Inc (IMUX) based on TradingKey's assessment. It highlights the company's current financial score of 7.02, ranking 166 out of 385 in the Biotechnology & Medical Research industry, indicating a robust financial status but low operating …

Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL

This article provides the "Price to book forward" value for Lyell Immunopharma, Inc. (NASDAQ: LYEL). It is a brief financial data point from TradingView, part of a larger financial overview for the company. The content primarily focuses on the specific metric within the platform's …

Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript

This article provides the transcript for Altimmune Inc.'s RECLAIM Phase 2 Trial in AUD Topline Results Conference Call held on July 28, 2026. The call began with an introduction by Louis Sine, Vice President of Investor Relations, and detailed how participants could ask questions. …

IMRX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Lack of Revenue - EPS Miss Report

SCNI Q4 2023 Earnings: Better-than-Expected Losses Amid No Revenue - Negative Surprise Momentum

Immunome (IMNM) Expected to Post Earnings on Wednesday

Immunitybio Inc (IBRX) Institutional Confidence

Immunitybio Inc (IBRX) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 20.71%, marking a 32.91% increase quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder, holding 557.67K shares.

IMUX|Immunic Inc|Price:13.271|Chg%:-0.539

This article provides a detailed stock analysis of Immunic Inc (IMUX) based on TradingKey's comprehensive stock score. It highlights Immunic's strong fundamentals and high growth potential, noting it's fairly valued within the Biotechnology & Medical Research industry. The analysis also covers high institutional ownership …

AC Immune SA (ACIU) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AC Immune SA (ACIU), noting its current risk score of 1.90 and ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 1.61, indicating higher volatility compared to the S&P 500, and …

Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com

This article reports on a Form 4 filing for Lyell Immunopharma Inc. dated July 27. It includes the stock symbol LYEL and its performance for the day. The article appears to be a brief financial news update from Investing.com.

Immutep Ltd (IMMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for Immutep Ltd (IMMP) concerns the company's revenue breakdown by business segments and regional contributions. However, it explicitly states that the relevant data for these breakdowns has not been disclosed by the company yet. Therefore, the article provides no specific financial details …

Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication

Altimmune has achieved a significant milestone in treating alcohol use disorder, a field also being explored by major pharmaceutical companies like Eli Lilly and Novo Nordisk. The article highlights Altimmune's efforts to innovate the treatment paradigm for this condition.

Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial

Altimmune's experimental GLP-1 drug, pemvidutide, significantly reduced heavy drinking days in a Phase 2 trial for alcohol use disorder. The drug, which targets both GLP-1 and glucagon receptors, also aims to treat the fatty liver disease MASH and showed a robust clinical profile compared …

BlackRock, Inc. (NYSE: BLK) discloses 6.7% ownership in Immuneering Corp (IMRX)

BlackRock, Inc. has disclosed a 6.7% ownership stake in Immuneering Corp (IMRX), as reported in a Schedule 13G SEC filing. This position amounts to 4,356,235 shares of Immuneering’s Class A stock as of June 30, 2026. BlackRock holds sole voting power over 4,314,766 shares …

ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by ImmunityBio, Inc. (NASDAQ:IBRX). The firm is encouraging investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to assist with the investigation. The investigation …

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – MUN:6YG

This article provides a revenue breakdown for Immunocore Holdings Plc (MUN:6YG). Last year, the company generated €340.58 million, with the Immunotherapies segment contributing the entire amount. The United States was the primary geographic contributor, accounting for €218.81 million of the total revenue.

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune announced positive top-line results from its RECLAIM Phase 2 trial for pemvidutide, showing significant reductions in heavy drinking days and improvements across secondary endpoints for alcohol use disorder. The drug also achieved significant body weight reduction and demonstrated a favorable tolerability profile. Altimmune …

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune's experimental drug pemvidutide successfully met its primary endpoint in a Phase II trial for alcohol use disorder (AUD), significantly reducing heavy drinking days and improving other key measures. The company plans to seek an FDA end-of-Phase-II meeting to discuss moving towards a Phase …

Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT

This page provides financial overview for Immunovant, Inc. (NASDAQ: IMVT). It indicates that the market is closed with no trades. The article is primarily a navigation and information hub for financial data on Immunovant, Inc., mentioning sections like "Fundamentals and stats," "Overview," "Statements," "Statistics," …

ALT Stock Holds Range As Traders Weigh Cash And Losses

Altimmune Inc. (ALT) stock is consolidating between $2.75 and $3.05 after recent selling pressure, despite a 12.16% surge driven by clinical trial progress. The company boasts a strong balance sheet with $331.5M in cash, providing a long funding runway, but continues to post significant …

ALT Stock Holds Range As Cash Runway Supports Speculative Trading

Altimmune Inc. (ALT) stock has been trading up by 11.82%, primarily driven by promising clinical trial progress. Despite recent sideways trading between $2.75 and $3.15, the company has a strong balance sheet with $97.6M in cash and minimal debt, providing a significant runway despite …

Altimmune rises as GLP-1 cuts drinking in mid-stage trial

Altimmune (ALT) shares rose over 15% in premarket trading after its GLP-1 candidate, pemvidutide, demonstrated a reduction in drinking in a mid-stage trial for patients with alcohol use disorder. The biotech company, headquartered in Gaithersburg, Maryland, released topline data from the study.

Scinai Immunotherapeutics Ltd

The article provides a revenue breakdown for Scinai Immunotherapeutics Ltd (SCNI), noting that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company. It briefly shows the current stock price, change, market cap, and indicates …

Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD

Altimmune announced positive topline Phase 2 results for its drug pemvidutide 2.4 mg in treating Alcohol Use Disorder (AUD), demonstrating a significant reduction in heavy drinking days compared to placebo. The RECLAIM study met its primary endpoint and two FDA-recognized secondary endpoints, showing favorable …

Altimmune stock surges 18% on positive trial results

Altimmune Inc. (NASDAQ:ALT) shares surged 18% after the company announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The trial met its primary and key secondary endpoints, showing a statistically significant reduction in heavy drinking days and …

ImmuCell Corp (ICCC) Income Statement

This article provides a detailed quarterly and annual income statement for ImmuCell Corp (ICCC), covering various financial metrics from total revenue to diluted earnings per share. It offers insights into the company's financial performance and operational efficiency over several fiscal years and quarters. The …

Immunic Q1 2026 Earnings: EPS Miss Overshadows Pipeline Progress; Stock Dips 3.4% - Earnings Season Preview

AC Immune (ACIU) Expected to Announce Quarterly Earnings on Tuesday

MindWalk Holdings (Nasdaq: HYFT) readies $250M shelf for AI-driven growth

MoonLake Immunotherapeutics (MLTX) Projected to Release Earnings on Tuesday

Immutep Ltd Sponsored ADR Revenue Breakdown – FWB:YP1A

The article provides a financial overview and market data for Immutep Ltd Sponsored ADR (FWB:YP1A) on the Frankfurt Stock Exchange. It highlights the company's financial statements, statistics, dividends, earnings, and segments, indicating a focus on its fundamental performance. No specific revenue breakdown figures are …

Lyell Immunopharma Market Sentiment

This article provides an overview of Lyell Immunopharma's (LYEL) market sentiment, detailing key signals such as analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with a high average price target, while options flow indicates a bearish sentiment with …